DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for misleading statements made during the Class Period from March 17, 2022, to September 22, 2022 [1][3] Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] Legal Proceedings - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who acquired Spectrum securities during the Class Period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Contact Information - Investors seeking more information can contact Andrew Abramowitz or Caitlin Adorni at Berger Montague [4][6]